Sonire Therapeutics, a U.S. based clinical-stage medical device company, announced $18M in Series A financing. The round was led by Santé Ventures with participation from Fast Track Initiative (FTI), Nomura SPARX Investment (Japan Growth Capital Investment Corporation), and SBI Investment, as well as other Japanese investors. The proceeds will accelerate clinical development, support U.S. regulatory progress following the company's 2024 FDA Breakthrough Device Designation, and advance global commercialization efforts for its innovative non-invasive cancer treatment.